On April 18, President Trump signed the Accelerating Medical Treatments for Serious Mental Illness executive order (EO) intended to “dramatically accelerate access to new medical research and treatments based on psychedelic drugs,” with an emphasis on ibogaine and psilocybin. The EO instructs the Food and Drug Administration (FDA) and Drug Enforcement Agency to create a method for patients to access these drugs under the existing Right to Try Act, which allows terminally ill patients to try experimental drugs outside of usual regulatory pathways. Both drugs will remain Schedule I controlled substances for the time being. The EO also commits $50 million to match state investments in psychedelic research.